Research programme: Alzheimer's disease therapy - Evotec NeuroSciences/Takeda

Drug Profile

Research programme: Alzheimer's disease therapy - Evotec NeuroSciences/Takeda

Alternative Names: Alzheimer's disease therapy research programme - Evotec NeuroSciences/Takeda

Latest Information Update: 14 Jan 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Evotec NeuroSciences
  • Developer Evotec NeuroSciences; Takeda
  • Class Small molecules
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Alzheimer's disease

Most Recent Events

  • 05 Aug 2003 Evotec and Takeda have entered into an agreement to co-develop this programme for Alzheimer's disease
  • 01 Aug 2003 Preclinical trials in Alzheimer's disease in Japan (unspecified route)
  • 24 Jun 2003 This programme is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top